Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)

about

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)

Item

http://www.wikidata.org/entity/Q58797772

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Heterogeneous prognosis among ...... eloid leukemia patients with t

@nl

Heterogeneous prognosis among ...... leukemia patients with t(8;21)

@en

type

Item

label

Heterogeneous prognosis among ...... eloid leukemia patients with t

@nl

Heterogeneous prognosis among ...... leukemia patients with t(8;21)

@en

prefLabel

Heterogeneous prognosis among ...... eloid leukemia patients with t

@nl

Heterogeneous prognosis among ...... leukemia patients with t(8;21)

@en

P1476

Heterogeneous prognosis among ...... leukemia patients with t(8;21)

@en

P2093

Hao Jiang

http://www.w3.org/2001/XMLSchema#string

Kai-Yan Liu

http://www.w3.org/2001/XMLSchema#string

Lan-Ping Xu

http://www.w3.org/2001/XMLSchema#string

Qian Jiang

http://www.w3.org/2001/XMLSchema#string

Xiao-Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao-Su Zhao

http://www.w3.org/2001/XMLSchema#string

Ya-Zhen Qin

http://www.w3.org/2001/XMLSchema#string

Yan-Rong Liu

http://www.w3.org/2001/XMLSchema#string

Yu Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.

Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.

P2888

s41408-018-0116-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41408-018-0116-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xiao-Jun Huang

Hong-Hu Zhu

P577

2018-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106016862

http://www.w3.org/2001/XMLSchema#string

P698

30087318

http://www.w3.org/2001/XMLSchema#string

P921

hematology

leukemia

P932

6081455

http://www.w3.org/2001/XMLSchema#string